Roggwil, March 31, 2020 – Resaphene Suisse AG, ISIN CH0367465439, WKN A2JG91, notified the withdrawal of inclusion in the Vienna MTF at the Vienna Stock Exchange on March 30th, 2020 in accordance with § 10 of the conditions for the operation of the Vienna MTF and the last one Trading day will be April 30th, 2020. In negotiations with investors, the inclusion in the Vienna MTF had proven to be an obstacle to the entry of private equity funds. The Board of Directors is now making a going private.
At the group level, the 1st quarter is currently developing into the best quarter in the company’s history. This year, the FDA approval is to be obtained in order to bring the tinnitus therapy device tinniwell to the US market.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016. The shares have been traded on the Vienna Stock Exchange in the Vienna MTF segment since June 2018. Resaphene Deutschland GmbH in Constance and Resaphene UK Ltd. in London and Resaphene US LLC in the US act as further sales companies.
++ Contact for questions:
Resaphene Suisse AG
Investor Relations contact:
Ms. Anke Rauterkus (Chief Executive Officer)